Revolutionizing Viral Production: The Shift to Chemically Defined Vero Cell Media
The Vero cell line, derived from the kidney epithelial cells of the African Green Monkey, has long been the "gold standard" for vaccine manufacturing. However, as of 2026, the research landscape has shifted dramatically. The industry is moving away from traditional media supplemented with Fetal Bovine Serum (FBS) toward Chemically Defined (CD) and Animal-Origin-Free (AOF) environments. This transition is not merely a trend but a critical evolution driven by regulatory pressure and the need for global scalability.
The Problem with Traditional Media
Historically, Vero cells—which are primarily anchorage-dependent—required serum to facilitate cell attachment and provide essential growth factors. While effective, serum-based media introduce several "unique" challenges:
Lot-to-Lot Variability: Natural serum varies in composition, leading to unpredictable viral yields.